STOCK TITAN
  1. Home
  2. News
  3. CVM

Cel-Sci Corp. - CVM STOCK NEWS

Welcome to our dedicated news page for Cel-Sci (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on Cel-Sci.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cel-Sci's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cel-Sci's position in the market.

News
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
Rhea-AI Summary
CEL-SCI (NYSE American: CVM) appoints Mario Gobbo, a seasoned expert in healthcare and energy finance, to its Board of Directors. With extensive experience in venture capital, private equity, and investment banking, Mr. Gobbo's addition brings valuable insights to the company's strategic growth. His background in successful healthcare ventures and strong industry connections positions CEL-SCI for advancements in medical breakthroughs, particularly in head and neck cancer treatment with the Multikine product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management
-
News
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Rhea-AI Summary
CEL-4000, a potential therapy for rheumatoid arthritis (RA), aims to rebalance the inflammatory response without compromising immune defense mechanisms. The article discusses the benefits of CEL-4000 compared to current RA treatments, emphasizing its potential to provide safe and effective therapy for RA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
News
CEL-SCI Corporation Issues Letter to Shareholders
Rhea-AI Summary
CEL-SCI Corporation (CVM) issues a letter to shareholders detailing successful advancements in the Multikine cancer therapy, presenting promising results from the Phase 3 trial. The company identified a target population for Multikine with significant survival benefits and presented key findings at a major oncology conference. The target population consists of newly diagnosed squamous cell carcinoma of the head and neck patients with specific characteristics, making them ideal candidates for Multikine treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
none
News
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
Rhea-AI Summary
CEL-SCI Corporation (CVM) reported financial results and key clinical & corporate developments for Multikine® in head and neck cancer patients. Recent data presented at ESMO Congress showed a 73% survival rate with Multikine vs 45% in control, with a 28% absolute survival benefit. Statistically significant results with no safety concerns. Target population identified for regulatory filings, estimated at 145,000 global patients annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
earnings
-
News
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Rhea-AI Summary
CEL-SCI Corporation (CVM) closes a public offering of 3,875,000 shares of common stock at $2.00 per share, raising $7.75 million for continued development of Multikine* and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
offering
-
News
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
Rhea-AI Summary
CEL-SCI Corporation (CVM) announces a public offering of 3,875,000 shares of common stock at $2.00 per share, aiming to raise $7.75 million for further development of Multikine and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
offering
News
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
Rhea-AI Summary
CEL-SCI Corporation completes the commissioning of its Multikine manufacturing facility, a key step in preparing for regulatory approval for the treatment of head and neck cancer. The facility has been expanded and upgraded in anticipation of filing a Biologics License Application with the FDA and other regulators. This achievement signifies a significant milestone in bringing Multikine to market, and the company's CEO emphasizes the high value of their manufacturing trade secret, capability, and know-how.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
-
News
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) has received a product-specific waiver from the European Medicines Agency (EMA) Paediatric Committee, allowing them to commercialize their cancer immunotherapy Multikine in the European Union. This waiver is a significant step forward for the company, as it eliminates a major hurdle in their path towards commercialization in Europe. The waiver ensures that the company does not face delays in their plans for commercialization. The EU Paediatric Regulation, enacted in 2007, aims to strengthen the investigation and development of medicinal products for the pediatric population. This regulatory change has a direct impact on CEL-SCI's ability to bring Multikine to the market in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
News
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. The company identified the target head and neck cancer patient population for Multikine, which saw a 73% survival rate vs 45% in the control at 5 years. The UK's National Institute for Health and Care Excellence (NICE) selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck. Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression. Financially, research and development expenses decreased by 11% and general and administrative expenses decreased by 16%. Net loss narrowed by 12% to approximately $32.2 million for the twelve months ended September 30, 2023 from $36.7 million in fiscal 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
earnings
News
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.27%
Tags
none
Stock CVM logo
Cel-Sci Corp.

NYSE:CVM

CVM Rankings

#4444 Ranked by Market Cap
#5028 Ranked by Stock Gains
N/A Ranked by Dividends

CVM Stock Data

87.99M
48.49M
3.2%
12.44%
12.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Vienna

About CVM

cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.